S 20928

Drug Profile

S 20928

Latest Information Update: 22 May 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Class Hormones
  • Mechanism of Action Melatonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mood disorders; Obesity

Most Recent Events

  • 22 May 1997 Discontinued-Preclinical in Affective disorders in France (Unknown route)
  • 22 May 1997 Discontinued-Unspecified Phase in Obesity in France (Unknown route)
  • 17 Jul 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top